These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28391915)

  • 1. Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism.
    Morena M; Le May C; Chenine L; Arnaud L; Dupuy AM; Pichelin M; Leray-Moragues H; Chalabi L; Canaud B; Cristol JP; Cariou B
    J Clin Lipidol; 2017; 11(1):87-93. PubMed ID: 28391915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
    Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
    Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 in chronic kidney disease.
    Pavlakou P; Liberopoulos E; Dounousi E; Elisaf M
    Int Urol Nephrol; 2017 Jun; 49(6):1015-1024. PubMed ID: 28084558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy.
    Konarzewski M; Szolkiewicz M; Sucajtys-Szulc E; Blaszak J; Lizakowski S; Swierczynski J; Rutkowski B
    Am J Nephrol; 2014; 40(2):157-63. PubMed ID: 25171595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients.
    Dounousi E; Tellis C; Pavlakou P; Duni A; Liakopoulos V; Mark PB; Papagianni A; Tselepis AD
    Oxid Med Cell Longev; 2021; 2021():6677012. PubMed ID: 34336112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels.
    Abujrad H; Mayne J; Ruzicka M; Cousins M; Raymond A; Cheesman J; Taljaard M; Sorisky A; Burns K; Ooi TC
    Atherosclerosis; 2014 Mar; 233(1):123-9. PubMed ID: 24529132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 in diabetic kidney disease.
    Elewa U; Fernández-Fernández B; Mahillo-Fernández I; Martin-Cleary C; Sanz AB; Sanchez-Niño MD; Ortiz A
    Eur J Clin Invest; 2016 Sep; 46(9):779-86. PubMed ID: 27438893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of a 1-year lifestyle modification program on plasma lipoprotein and PCSK9 concentrations in patients with coronary artery disease.
    Boyer M; Lévesque V; Poirier P; Marette A; Mathieu P; Després JP; Larose É; Arsenault BJ
    J Clin Lipidol; 2016; 10(6):1353-1361. PubMed ID: 27919352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and Estimated Glomerular Filtration Rate in the General Chinese Population.
    Zhang HW; Zhao X; Xu RX; Guo YL; Zhu CG; Wu NQ; Cui CJ; Dong Q; Li JJ
    Cardiorenal Med; 2018; 8(4):311-320. PubMed ID: 30121647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between circulating proprotein convertase subtilisin/kexin type 9 levels and prognosis in patients with severe chronic kidney disease.
    Rasmussen LD; Bøttcher M; Ivarsen P; Jørgensen HS; Nyegaard M; Buttenschøn H; Gustafsen C; Glerup S; Bøtker HE; Svensson M; Winther S
    Nephrol Dial Transplant; 2020 Apr; 35(4):632-639. PubMed ID: 30137516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients.
    Bermudez-Lopez M; Forne C; Amigo N; Bozic M; Arroyo D; Bretones T; Alonso N; Cambray S; Del Pino MD; Mauricio D; Gorriz JL; Fernandez E; Valdivielso JM
    Expert Opin Ther Targets; 2019 Jul; 23(7):619-630. PubMed ID: 31100024
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
    Constantinides A; Kappelle PJ; Lambert G; Dullaart RP
    Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDL Cholesterol, LDL Cholesterol, and Triglycerides as Risk Factors for CKD: A Mendelian Randomization Study.
    Lanktree MB; Thériault S; Walsh M; Paré G
    Am J Kidney Dis; 2018 Feb; 71(2):166-172. PubMed ID: 28754456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR.
    Rogacev KS; Heine GH; Silbernagel G; Kleber ME; Seiler S; Emrich I; Lennartz S; Werner C; Zawada AM; Fliser D; Böhm M; März W; Scharnagl H; Laufs U
    PLoS One; 2016; 11(1):e0146920. PubMed ID: 26799206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
    J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
    Ridker PM; Rifai N; Bradwin G; Rose L
    Eur Heart J; 2016 Feb; 37(6):554-60. PubMed ID: 26508163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K; Park BS; Kim YW; Vaziri ND
    Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response.
    Ooi TC; Krysa JA; Chaker S; Abujrad H; Mayne J; Henry K; Cousins M; Raymond A; Favreau C; Taljaard M; Chrétien M; Mbikay M; Proctor SD; Vine DF
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3452-3460. PubMed ID: 28673045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.